Results for tag: "CB 839"

The CB 839 market is a subset of the kidney cancer drug market, which is composed of treatments for renal cell carcinoma (RCC). RCC is the most common type of kidney cancer, and is typically treated with a combination of surgery, radiation, and chemotherapy. CB 839 is a novel, orally administered small molecule inhibitor of the enzyme glutaminase, which is involved in the metabolism of glutamine, an amino acid. It is being developed as a potential treatment for RCC, and is currently in clinical trials. CB 839 is being developed by several companies, including Novartis, Merck, and AstraZeneca. Novartis is developing the drug in collaboration with the biotechnology company, Exelixis, while Merck is developing it in partnership with the biopharmaceutical company, OncoMed Pharmaceuticals. AstraZeneca is also developing the drug in collaboration with the biotechnology company, Daiichi Sankyo. Show Less Read more